Valuation: Immuneering Corporation

Market Cap 279M 245M 228M 209M 394M 26.92B 400M 2.71B 1.06B 13.23B 1.05B 1.03B 45.75B P/E 2026 *
-3.88x
P/E 2027 * -3.36x
Enterprise Value 279M 245M 228M 209M 394M 26.92B 400M 2.71B 1.06B 13.23B 1.05B 1.03B 45.75B EV / Sales 2026 *
-
EV / Sales 2027 * 14.3x
Free-Float
86.52%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Immuneering Corporation

1 day-1.59%
1 week-6.90%
Current month-13.43%
1 month-6.09%
3 months-28.48%
6 months-19.40%
Current year-34.35%
1 week 4.27
Extreme 4.27
4.91
1 month 4.27
Extreme 4.27
5.7
Current year 3.86
Extreme 3.86
8.48
1 year 2.9
Extreme 2.9
10.08
3 years 1
Extreme 1
10.99
5 years 1
Extreme 1
33.99
10 years 1
Extreme 1
33.99
Manager TitleAgeSince
Chief Executive Officer 44 2008-01-31
Director of Finance/CFO 61 2026-07-15
Chief Tech/Sci/R&D Officer - 2023-07-31
Director TitleAgeSince
Director/Board Member 72 2021-04-26
Chairman 81 2007-12-31
Chairman 66 2025-09-15
Date Insider Type Main position Quantity % Market Cap.
7/16/26 Other

Chief Financial Officer

225,000 0.3478%
7/16/26 Free

Chief Financial Officer

650,000 1.0047%
6/23/26 Buy

Founder

2,400 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
-1.59%-6.90%+8.00%-57.81% 279M
+0.93%+6.97%+62.83%+67.97% 57.28B
-1.92%+6.03%+43.68%+84.56% 54.99B
-0.46%-1.29%+3.28%+422.58% 23.18B
-2.97%-2.35%-22.03%-16.54% 22.59B
-0.36%+5.73%+30.99%-3.58% 20.46B
-1.34%+0.51%+25.02%-30.27% 17.56B
-1.44%+5.67%+32.54%+544.11% 15.67B
-1.30%-5.02%+165.62%+291.37% 14.46B
-0.50%-0.98%+23.62%+178.38% 13.92B
Average -1.10%+0.46%+37.36%+148.08% 24.04B
Weighted average by Cap. -0.87%+2.08%+41.14%+135.46%

Financials

2026 *2027 *
Net sales - 19.5M 17.13M 15.93M 14.62M 27.46M 1.88B 27.88M 189M 73.89M 923M 73.2M 71.63M 3.19B
Net income -74.87M -65.76M -61.15M -56.12M -105M -7.21B -107M -726M -284M -3.54B -281M -275M -12.26B -87.34M -76.71M -71.34M -65.46M -123M -8.41B -125M -847M -331M -4.13B -328M -321M -14.3B
Net Debt - -
Logo Immuneering Corporation
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.
Employees
55
Date Price Change Volume
26-07-24 US$4.320 -1.59% 465,316
26-07-23 US$4.390 -1.79% 514,556
26-07-22 US$4.470 +0.22% 616,125
26-07-21 US$4.460 +3.96% 759,522
26-07-20 US$4.290 -7.54% 1,198,598
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.320USD
Average target price
18.86USD
Spread / Average Target
+336.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMRX Stock